Vaccines for malaria: How close are we?

Annual Review of Medicine

Volumn 63, Issue , 2012, Pages 345-357

  Thera, Mahamadou A ^a   Plowe, Christopher V ^b  

^a UNIVERSITY OF BAMAKO   (Mali)

^b University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Malaria eradication; Malaria immunity; Malaria prevention; Plasmodium falciparum; Subunit vaccines; Whole organism vaccines

Indexed keywords

IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; RECOMBINANT PROTEIN;

AFRICA; ANOPHELES; ERYTHROCYTE; GAMETE; GAMETOCYTE; HUMAN; LIVER CELL; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; OOCYST; PARASITE IMMUNITY; PARASITE VECTOR; PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM KNOWLESI MALARIA; PLASMODIUM MALARIAE; PLASMODIUM MALARIAE INFECTION; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; REVIEW; SPOROZOITE;

AFRICA; HUMANS; MALARIA; MALARIA VACCINES; PUBLIC HEALTH;

EID: 84855923570     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-022411-192402     Document Type: Review

References (64)

1. World Health Organization, Roll Back Malaria Partnership. 2008. The global malaria action plan for a malaria free world. Available at http://www.rbm.who.int/gmap/. Accessed Aug. 17, 2011
2. Tanner M, de Savigny D. 2008. Malaria eradication back on the table. Bull. World Health Organ. 86:82 (Pubitemid 351213705)
3. Plowe CV, Alonso P, Hoffman SL. 2009. The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J. Infect. Dis. 200:1646-49
4. Henderson DA. 1999. Lessons from the eradication campaigns. Vaccine 17(Suppl. 3):S53-S55 (Pubitemid 29516681)
5. malERA Consultative Group on Vaccines. 2011. A research agenda for malaria eradication: vaccines. PLoS Med. 8:e1000398
6. Su X, Heatwole VM, Wertheimer SP, et al. 1995. The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 82:89-100
7. Duffy PE. 2007. Plasmodium in the placenta: parasites, parity, protection, prevention and possibly preeclampsia. Parasitology 134:1877-81 (Pubitemid 350014550)
8. Gardner MJ, Hall N, Fung E, et al. 2002. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419:498-511
9. Takala SL, Plowe CV. 2009. Genetic diversity andmalaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol. 31:560-73
10. Takala SL, Coulibaly D, Thera MA, et al. 2007. Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med. 4:e93
11. Takala SL, Coulibaly D, Thera MA, et al. 2009. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci. Transl. Med. 1:2ra5
12. Alonso PL, Sacarlal J, Aponte JJ, et al. 2004. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364:1411-20 (Pubitemid 39370716)
13. Ballou WR, Rothbard J, Wirtz RA, et al. 1985. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science 228:996-99 (Pubitemid 15028388)
14. Dame JB, Williams JL, McCutchan TF, et al. 1984. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225:593-99 (Pubitemid 14053761)
15. Hollingdale MR, Nardin EH, Tharavanij S, et al. 1984. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J. Immunol. 132:909-13 (Pubitemid 14189116)
16. Gordon DM, McGovern TW, Krzych U, et al. 1995. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171:1576-85
17. Stoute JA, Slaoui M, Heppner DG, et al. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS, S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336:86-91 (Pubitemid 27020884)
18. Bojang KA, Milligan PJ, Pinder M, et al. 2001. Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358:1927-34 (Pubitemid 34072872)
19. Bejon P, Lusingu J, Olotu A, et al. 2008. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359:2521-32
20. Sacarlal J, Aide P, Aponte JJ et al. 2009. Long-term safety and efficacy of the RTS, S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis. 200:329-36
21. Heppner DG Jr., Kester KE, Ockenhouse CF, et al. 2005. Towards an RTS, S-based, multi-stage, multiantigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23:2243-50 (Pubitemid 40341460)
22. Stewart VA, McGrath SM, Dubois PM, et al. 2007. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS, S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun. 75:2283-90 (Pubitemid 46744316)
23. World Health Organization. 2010. Initiative for vaccine research: malaria vaccines. Available at http://www. who. int/vaccine-research/links/Rainbow/en/ index. html. Accessed Aug. 17, 2011
24. Cummings JF, Spring MD, Schwenk RJ, et al. 2010. Recombinant liver stage antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine 28:5135-44
25. Hill AV, Reyes-Sandoval A, O'Hara G, et al. 2010. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 6:78-83
26. Kaba SA, Brando C, Guo Q, et al. 2009. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J. Immunol. 183:7268-77
27. Bergmann-Leitner ES, Mease RM, De La Vega P, et al. 2010. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS ONE 5:e12294
28. Riley EM, Allen SJ, Wheeler JG, et al. 1992. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol. 14:321-37
29. Thera MA, Doumbo OK, Coulibaly D, et al. 2006. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clin. Trials 1:e34
30. Ogutu BR, Apollo OJ, McKinney D, et al. 2009. Blood stage malaria vaccine eliciting high antigenspecific antibody concentrations confers no protection to young children inWestern Kenya. PLoS ON E. 4:e4708
31. Peterson MG, Marshall VM, Smythe JA, et al. 1989. Integral membrane protein located in the apical complex of Plasmodium falciparum. Mol. Cell Biol. 9:3151-54 (Pubitemid 19163087)
32. Mitchell GH, Thomas AW, Margos G, et al. 2004. Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect. Immun. 72:154-58 (Pubitemid 38018172)
33. Florens L, Washburn MP, Raine JD, et al. 2002. A proteomic view of the Plasmodium falciparum life cycle. Nature 419:520-26
34. Hodder AN, Crewther PE, Anders RF. 2001. Specificity of the protective antibody response to apical membrane antigen 1. Infect. Immun. 69:3286-94 (Pubitemid 32332227)
35. Polley SD, Mwangi T, Kocken CH, et al. 2004. Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23:718-28 (Pubitemid 39473204)
36. Dutta S, Lee SY, Batchelor AH, et al. 2007. Structural basis of antigenic escape of a malaria vaccine candidate. Proc. Natl. Acad. Sci. USA 104:12488-93 (Pubitemid 47206165)
37. Healer J, Murphy V, Hodder AN, et al. 2004. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol. Microbiol. 52:159-68 (Pubitemid 38519629)
38. Sagara I, Dicko A, Ellis RD, et al. 2009. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 27:3090-98
39. Ouattara A, Mu J, Takala-Harrison S, et al. 2010. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar. J. 9:175
40. Thera MA, Doumbo OK, Coulibaly D, et al. 2010. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. PLoS ONE 5:e9041
41. Spring MD, Cummings JF, Ockenhouse CF, et al. 2009. Phase 1/2a study of themalaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02 A. PLoS ONE 4:e5254
42. Thera MA, Doumbo OK, Coulibaly D, et al. 2011. A field trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 365:1004-13
43. Sirima SB, Cousens S, Druilhe P. 2011. Protection against malaria by MSP3 candidate vaccine. N. Engl. J. Med. 365:1062-64
44. Remarque EJ, Faber BW, Kocken CH, et al. 2008. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect. Immun. 76:2660-70
45. Dutta S, Dlugosz LS, Clayton JW, et al. 2010. Alanine mutagenesis of the primary antigenic escape residue cluster, c1, of apical membrane antigen 1. Infect. Immun. 78:661-71
46. Smith JD, Chitnis CE, Craig AG, et al. 1995. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82:101-10
47. Klein MM, Gittis AG, Su HP et al. 2008. The cysteine-rich interdomain region from the highly variable Plasmodium falciparum erythrocyte membrane protein-1 exhibits a conserved structure. PLoS Pathog. 4:e1000147
48. Avril M, Cartwright MM, Hathaway MJ, et al. 2010. Immunization with VAR2CSA-DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium falciparum-infected erythrocytes. Infect. Immun. 78:2248-56
49. Barr PJ, Green KM, Gibson HL, et al. 1991. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 174:1203-8
50. Wu Y, Ellis RD, Shaffer D, et al. 2008. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 3:e2636
51. Dinglasan RR, Valenzuela JG, Azad AF. 2005. Sugar epitopes as potential universal disease transmission blocking targets. Insect Biochem. Mol. Biol. 35:1-10 (Pubitemid 40015506)
52. Valero MV, Amador LR, Galindo C, et al. 1993. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 341:705-10 (Pubitemid 23085175)
53. D'Alessandro U, Leach A, Drakeley CJ, et al. 1995. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 346:462-67
54. Alonso PL, Smith T, Schellenberg JR, et al. 1994. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344:1175-81 (Pubitemid 24323705)
55. Ockenhouse CF, Sun PF, Lanar DE, et al. 1998. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177:1664-73 (Pubitemid 28243593)
56. Kumar S, Epstein JE, Richie TL, et al. 2002. A multilateral effort to develop DNA vaccines against falciparum malaria. Trends Parasitol. 18:129-35 (Pubitemid 34164258)
57. Freund J, Thomson KJ, Sommer HE, et al. 1945. Immunization of rhesus monkeys against malarial infection ( P. knowlesi ) with killed parasites and adjuvants. Science 102:202-4
58. Clyde DF, Most H, McCarthy VC, et al. 1973. Immunization of man against sporozite-induced falciparum malaria. Am. J. Med. Sci. 266:169-77
59. Luke TC, Hoffman SL. 2003. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206:3803-8 (Pubitemid 37365462)
60. Hoffman SL, Billingsley PF, James E, et al. 2010. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 6:97-106
61. Epstein JE, Tweari K, Lyke KE, et al. 2011. Live attenuated malaria vacine designed to protect through hepatic D8+ T cell immunity. Science 334:475-80
62. VanBuskirk KM, O'Neill MT, De La Vega P, et al. 2009. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc. Natl. Acad. Sci USA 106:13004-9
63. McCarthy JS, Good MF. 2010. Whole parasite blood stage malaria vaccines: a convergence of evidence. Hum. Vaccin. 6:114-23
64. Lyke KE, Laurens M, Adams M, et al. 2010. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS ON E. 5:e13490